Resverlogix to host Conference Call & Webcast with Q&A

TSX Exchange Symbol: RVX

CALGARY, June 28, 2013 /PRNewswire/ - Resverlogix will be hosting a conference call and webcast with live Q&A on Tuesday, July 2, 2013 at 11 am MDT.

Details for the conference call and webcast are as follows:

Link to webcast: http://services.choruscall.ca/links/resverlogix130702.html

Dial in numbers:

Canada & USA Toll Free Dial In: 1-800-319-4610
Outside of Canada & USA call: +1-604-638-5340  

About Resverlogix

Resverlogix Corp. (TSX:RVX) is a clinical stage cardiovascular company developing compounds involving a therapeutic increase in ApoA-I. Resverlogix's RVX-208 is a first-in-class small molecule for the treatment of atherosclerosis and other chronic diseases such as diabetes mellitus and Alzheimer's disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of atherosclerosis. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contacts:
       
Donald J. McCaffrey     Sarah Zapotichny
President and CEO     Director of Investor Relations
Resverlogix Corp.     Resverlogix Corp.
Phone: 403-254-9252      Phone: 403-254-9252
Email: don@resverlogix.com     Email: sarah@resverlogix.com
     

SOURCE Resverlogix Corp.



More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.